Shiga Toxin Producing Bacterial Infection

Infectious Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

LFB
LFBFrance - Paris
1 program
1
cαStx1/cαStx2Phase 21 trial
Active Trials
NCT01252199Completed45Est. Feb 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LFBcαStx1/cαStx2

Clinical Trials (1)

Total enrollment: 45 patients across 1 trials

NCT01252199LFBcαStx1/cαStx2

Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2

Start: Nov 2010Est. completion: Feb 201345 patients
Phase 2Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space